LIBRETTO-001: Phase I Trial of LOXO-292, a Novel RET Inhibitor, in Patients With RET-Altered Advanced Solid Tumors

June 1-5, 2018; Chicago, Illinois
LOXO-292 showed robust and durable activity in previously treated patients with RET-altered tumors, including NSCLC, regardless of prior therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 218 KB
Released: June 5, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

EHR data analysis from ASCO 2021 showed that NGS testing and clinical trial participation were less likely among Black patients with NSCLC than White patients, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Download these expert-selected slides on testing for TRK fusions in your patients with cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Released: June 11, 2021

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue